136 related articles for article (PubMed ID: 9850444)
1. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral.
First MR; Alloway R; Schroeder TJ
Clin Transplant; 1998 Dec; 12(6):518-24. PubMed ID: 9850444
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral.
Schroeder TJ; Cho MJ; Pollack GM; Floc'h R; Moran HB; Levy R; Moore LW; Pouletty P
J Clin Pharmacol; 1998 Sep; 38(9):807-14. PubMed ID: 9753208
[TBL] [Abstract][Full Text] [Related]
3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
4. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
[No Abstract] [Full Text] [Related]
5. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
[TBL] [Abstract][Full Text] [Related]
7. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation.
Roza A; Tomlanovich S; Merion R; Pollak R; Wright F; Rajagopalan P; Pruett T; Scandling J; Ryan J; Awni W; Schweitzer S; Greco R; Lam W; Nabulsi A; Hoffman R
Transplantation; 2002 Oct; 74(7):1013-7. PubMed ID: 12394847
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
9. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
[TBL] [Abstract][Full Text] [Related]
12. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients.
Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972
[TBL] [Abstract][Full Text] [Related]
13. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
[TBL] [Abstract][Full Text] [Related]
14. Neoral use in the cardiac transplant recipient.
Valantine H
Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
[TBL] [Abstract][Full Text] [Related]
15. Bioequivalence of a new cyclosporine a formulation to Neoral.
David-Neto E; Kakehashi E; Alves CF; Pereira LM; de Castro MC; de Mattos RM; Sumita NM; Romano P; Mendes ME; Nahas WC; Ianhez LE
Ther Drug Monit; 2004 Feb; 26(1):53-7. PubMed ID: 14749551
[TBL] [Abstract][Full Text] [Related]
16. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
Mahalati K; Belitsky P; Sketris I; West K; Panek R
Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
[TBL] [Abstract][Full Text] [Related]
17. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
[TBL] [Abstract][Full Text] [Related]
18. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
[TBL] [Abstract][Full Text] [Related]
20. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
Sperschneider H; Wagner C; Korn A; Christians U
Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
